OakChart

BioNTech SE ADR

BNTXHealthcare·Biotechnology·Germany·Large·NASD·Nov 11 • 11:14 AM ET

87.29+0.08 (0.09%)
2026-11-11 17:14 CET
Market cap
21,621.80 USD m
Revenue, TTM
2,800.35 USD m
Net income, TTM
-1,719.36 USD m
Free cash flow, TTM
-517.58 USD m
EPS diluted, TTM
-6.87
P/E
-
Compare

Price

BNTX against its 20, 50 and 200-day averages
2050200beatmiss
90.00100.00110.00120.004.4M8.8MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26BNTXclose 87.2920-day 88.3650-day 93.79200-day 96.0587.29

29.6% under the 52-week high of 124.00 on 22 Jan 2026. 52-week low 79.52 on 10 Mar 2026. Last 15 sessions, 9.2% high to low

Profile

BNTX
52-week range, 17% of the way up
79.52124

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Employees7807
IPOOct 10, 2019
Beta1.32
ATR, 14d2.85
Rel volume0.61
Short float0.91%
Insider own0.43%
Inst own18.84%

Snapshot

6 groups

Valuation

Index-
Market Cap21.64B
Enterprise Value6.39B
Income-1.72B
Sales2.80B
Book/sh81.14
Cash/sh63.86
Dividend Est.-
Dividend TTM-
Dividend Ex-DateJun 02, 2022
Dividend Gr. 3/5Y- -
Payout-
Employees7807
IPOOct 10, 2019

Ratios

P/E-
Forward P/E-
PEG-
P/S7.73
P/B1.08
P/C1.37
P/FCF-
EV/EBITDA-
EV/Sales2.28
Quick Ratio8.52
Current Ratio8.55
Debt/Eq0.03
LT Debt/Eq0.02
Option/ShortYes / Yes

Earnings

EPS (ttm)-6.87
EPS next Y-6.23
EPS next Q-1.87
EPS this Y-22.45%
EPS next Y3.09%
EPS next 5Y3.20%
EPS past 3/5Y- -
Sales past 3/5Y-43.74% 42.57%
EPS Y/Y TTM-160.57%
Sales Y/Y TTM-20.72%
EPS Q/Q702.08%
Sales Q/Q-16.44%
EarningsNov 03 BMO
EPS/Sales Surpr.8.96% 24.53%

Ownership

Insider Own0.43%
Insider Trans-44.60%
Inst Own18.84%
Inst Trans-1.09%
ROA-7.17%
ROE-8.22%
ROIC-8.42%
Gross Margin50.99%
Oper. Margin-61.20%
Profit Margin-61.40%
SMA20-1.21%
SMA50-6.93%
SMA200-9.12%
Trades-

Technical

Shs Outstand247.93M
Shs Float246.87M
Short Float0.91%
Short Ratio1.84
Short Interest2.25M
52W High124.00 -29.61%
52W Low79.52 9.77%
Volatility3.53% 3.07%
ATR (14)2.85
RSI (14)43.03
Beta1.32
Rel Volume0.61
Avg Volume1.22M
Volume227,660

Performance

Perf Week-3.76%
Perf Month-1.93%
Perf Quarter-5.25%
Perf Half Y-5.36%
Perf YTD-8.31%
Perf Year-19.66%
Perf 3Y-12.33%
Perf 5Y-62.50%
Perf 10Y-
Recom1.76
Target Price115.09
Prev Close87.21
Price87.29
Change %0.09%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Oct 08, 2026InitiatedAArgusHold
Sep 08, 2026DowngradeBBMO Capital MarketsOutperform → Market Perform$105+20.3%
May 27, 2026UpgradeUUBSNeutral → Buy$135+54.7%
May 22, 2026InitiatedBBernsteinMkt Perform$96+10.0%
Feb 02, 2026DowngradeLLeerink PartnersOutperform → Market Perform$113+29.5%
Jan 16, 2026UpgradeGGoldmanNeutral → Buy$142+62.7%
Jun 05, 2025ReiteratedHH.C. WainwrightBuy$134 → $145+66.1%
May 29, 2025InitiatedGGoldmanNeutral$110+26.0%
Mar 13, 2025InitiatedCCitigroupBuy$145+66.1%
Jan 10, 2025InitiatedTTruistBuy$172+97.0%

Peers

Mkt cap
TickerCompanyMkt cap
MRNAModerna Inc99.86B
SMMTSummit Therapeutics Inc13.58B
GMABGenmab ADR32.65B
ARCTArcturus Therapeutics Holdings Inc269.33M
NVAXNovavax Inc1.66B
ONCBeOne Medicines Ltd ADR44.33B
REGNRegeneron Pharmaceuticals Inc94.81B
PFEPfizer Inc166.61B
PCVXVaxcyte Inc10.74B
IOVAIovance Biotherapeutics Inc3.75B

Insider trading

latest 14 of 33
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Sahin UgurChief Executive OfficerOct 09 '26Sale95.3736,2093,453,3720Oct 09 04:47 PM
Sahin UgurChief Executive OfficerOct 08 '26Sale92.3127,0002,492,48336,209Oct 09 04:47 PM
Sahin UgurChief Executive OfficerOct 07 '26Sale95.8624,0002,300,63363,209Oct 07 05:14 PM
Sahin UgurChief Executive OfficerOct 05 '26Sale97.2372,0007,000,646108,209Oct 06 04:59 PM
Sahin UgurChief Executive OfficerOct 06 '26Sale96.8121,0002,032,99587,209Oct 06 04:59 PM
Sahin UgurChief Executive OfficerOct 01 '26Sale97.4617,0001,656,745197,209Oct 02 04:27 PM
Sahin UgurChief Executive OfficerOct 02 '26Sale96.7217,0001,644,323180,209Oct 02 04:27 PM
Sahin UgurChief Executive OfficerSep 29 '26Sale98.2634,0003,340,809246,209Sep 30 04:29 PM
Sahin UgurChief Executive OfficerSep 30 '26Sale98.1232,0003,139,850214,209Sep 30 04:29 PM
Sahin UgurChief Executive OfficerSep 28 '26Sale98.4734,0003,347,919280,209Sep 28 05:16 PM
Sahin UgurChief Executive OfficerSep 25 '26Sale98.6927,0002,664,581314,209Sep 28 05:16 PM
Sahin UgurChief Executive OfficerSep 24 '26Sale98.9939,0003,860,661341,209Sep 24 04:26 PM
Sahin UgurChief Executive OfficerSep 23 '26Sale99.4030,0002,982,081380,209Sep 24 04:26 PM
Sahin UgurChief Executive OfficerSep 22 '26Sale100.7246,0004,633,037410,209Sep 22 05:04 PM

Held by

AUM
TickerCompanyAUM
FBTFirst Trust NYSE Arca Biotechnology Index FundAUM: 3.03B
IBBiShares Biotechnology ETFAUM: 11.36B
FNDFSchwab Fundamental International Equity ETFAUM: 25.65B
IDNAiShares Genomics Immunology and Healthcare ETFAUM: 354.14M
SPDWState Street SPDR Portfolio Developed World ex-US ETFAUM: 41.64B
BBHVanEck Biotech ETFAUM: 536.31M
BBEUJPMorgan BetaBuilders Europe ETFAUM: 9.24B
QQQJInvesco NASDAQ Next Gen 100 ETFAUM: 1.17B
IALTiShares Systematic Alternatives Active ETFAUM: 7.83B
BBINJPMorgan BetaBuilders International Equity ETFAUM: 6.56B

News

latest 14 of 206
  • BioNTech Crushes Estimates On A BMS-Boosted Quarter, But Late-Stage Setbacks Leave Shares Near Their Lows (Earnings Whispers)
  • Pfizer Finds Life Beyond the Pandemic as Earnings Top Estimates (Barrons.com)
  • BioNTech Announces Third Quarter 2026 Financial Results and Corporate Update (GlobeNewswire)
  • BioNTech Heads Into Its Key Vaccine Quarter With A Lowered Bar And Shaken Confidence (Earnings Whispers)
  • BioNTech and DualityBio Announce Topline Results of the DYNASTY-Breast02 Global Phase 3 Clinical Trial Evaluating Trastuzumab Pamirtecan in HR+/HER2-low Metastatic Breast Cancer (GlobeNewswire)
  • Loading…
  • BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapy (GlobeNewswire)
  • Moderna's Cancer-Vaccine Leak Spurred Panic Selling as Wall Street Wanted a Cure (Barrons.com)
  • BioNTech Advances Phase 3 Clinical Trial of Pumitamig in Combination with Gilead's TROP2-Directed ADC Sacituzumab Govitecan in Triple-Negative Breast Cancer (GlobeNewswire)
  • BioNTech to Report Third Quarter 2026 Financial Results and Corporate Update on November 3, 2026 (GlobeNewswire)
  • BioNTech to Showcase Oncology Late-Stage Pipeline Progress and Pumitamig Novel-Novel Combination Data at ESMO 2026 (GlobeNewswire)
  • BioNTech Shares Fall 5% as BNT113 Cancer Trial Misses Progression-Free Survival Endpoint (InvestorsHub) -7.13%
  • BioNTech stock falls after cancer trial misses key endpoint (Investing.com)
  • BioNTech Provides Update on Phase 2/3 Clinical Trial for mRNA Cancer Immunotherapy Candidate BNT113 in Metastatic HPV16-positive Head and Neck Cancer (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-030.8170.7500.8171,4431,15913
2026Q22026-08-04-3.728-2.420-3.799121.51181.813
2026Q12026-05-05-2.455-2.567-2.461138.08209.7613
2025Q42026-03-10-1.452-0.191-1.4481,054905.6615
2025Q32025-11-03-0.138-1.107-0.1401,751838.1313
2025Q22025-08-04-1.854-2.608-1.823302.21177.4212
2025Q12025-05-05-1.959-2.587-1.821206.95228.9615
2024Q42025-03-101.1730.4821.1541,2921,23016
2024Q32024-11-040.881-1.6700.8901,353559.5212
2024Q22024-08-05-3.666-2.188-3.658140.42145.9914
2024Q12024-05-06-1.409-1.333-1.422201.83476.2212
2023Q42024-03-202.0632.5772.0351,6061,98613
2023Q32023-11-060.719-0.6250.729960.43900.5610
2023Q22023-08-07-0.870-0.911-0.864184.58686.8510
2023Q12023-05-082.2590.2912.2001,4071,16710
2022Q42023-03-279.9788.3629.4404,6103,9289

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-0.933-0.813-0.948119.15122.23
2020FY0.070-1.8680.070565.65432.67
2021FY44.24539.98646.84521,18719,011
2022FY40.70037.80539.69318,65317,927
2023FY4.1604.6624.1444,1484,534
2024FY-3.008-3.567-2.9942,9882,865
2025FY-5.460-4.141-5.4603,3343,209
2026FY--6.426--2,094
2027FY--6.228--2,077
2028FY--4.761--2,602
2029FY--4.236--2,430
2030FY--3.053--3,116

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-061338439.4312.43672.84
2026Q4S2026-11-051237445.93312.69673.39
2026Q4S2026-11-031237444.52311.69671.23
2026Q4S2026-10-231221573.86388.24766.39
2026Q4S2026-10-181221573.44387.96765.82
2026Q4S2026-10-161238573.44387.96765.82
2026Q4S2026-10-151238572.52387.33764.59
2026Q4S2026-10-141238577.18387.56765.04
2026Q4S2026-10-091238577.81387.96765.84
2026Q4S2026-09-2912110578.67393.43776.62
2026Q4S2026-09-1412110589.98401.14791.84
2026Q4S2026-09-1012110592.04402.54794.6
2026Q4S2026-09-0712111590.98401.82793.19
2026Q4S2026-08-2812110607.68403.21839.78

Estimate history

EPS, annual-10.428-5.344-0.9480.0746.84539.6934.144-2.994-5.305-6.868
Period201720182019202020212022202320242025TTM
EPS, quarterly0.891.154-1.821-1.823-0.14-1.448-2.461-3.7990.84
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual69.479150.507121.538549.83822430.09718192.9964128.782975.8393238.9062800.35
Period201720182019202020212022202320242025TTM
Sales, quarterly1367.4691269.364192.39295.6041775.0271056.152138.168122.7821483.25
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual-10.739226.78241.521242.521243.215237.726239.971251.325247.928
Period201720182019202020212022202320242025MRQ
Shares, quarterly239.74239.971240.393240.399240.455251.325252.884251.204247.928
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue2,800.353,238.912,975.844,128.7818,193.0022,430.10549.84121.54150.51
Cost of Goods Sold Incl. D&A1,372.45724.32585.52618.94166.26113.5967.2755.7340.47
Gross Profit1,427.902,514.582,390.323,509.8418,026.7322,316.51482.5665.81110.03
Selling, General and Administrative Excl. Other2,937.303,080.233,086.282,530.682,057.701,471.80786.46271.24179.08
Research and Development2,378.102,375.542,438.351,927.741,563.531,083.05676.96222.66147.15
Other Operating Expense204.42167.370.000.000.000.000.020.00-
Operating Income-1,713.82-733.01-695.96979.1715,969.0320,844.71-303.92-205.43-69.05
Interest Expense20.3416.0313.638.5417.036.382.281.922.03
Unusual Expense545.68733.58183.67-186.922,885.983,722.7796.160.360.06
Net Income Before Taxes-1,672.32-1,185.91-733.061,282.3113,614.4317,784.56-166.23-200.84-56.13
Income Taxes47.0596.27-13.41276.553,699.115,619.02-183.56-0.300.71
Consolidated Net Income-1,719.36-1,282.18-719.651,005.769,915.3112,165.5417.33-200.54-56.94
Net Income From Continuing Operations-1,719.36-1,282.18-719.651,005.769,915.3112,165.5417.33-200.41-56.65
Net Income-1,719.36-1,282.18-719.651,005.769,915.3112,165.5417.33-200.41-56.65
EPS (Recurring)-5.29-3.18-2.463.6047.7856.880.34-0.95-5.34
EPS (Basic, Before Extraordinaries)-6.85-5.30-2.994.1840.7549.860.07-0.95-5.34
EPS (Diluted)-6.87-5.30-2.994.1439.6946.840.07-0.95-5.34
EBITDA-688.38-300.99-373.621,177.4416,098.6120,933.59-259.75-167.49-43.12
Non-Operating Income (Expense)607.53296.70160.20124.76548.40669.00236.136.8815.01
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense71.8685.4877.7639.0996.4866.6025.5723.69-
Price To Earnings Ratio---9.063.215.09767.59--
Price To Sales Ratio8.877.109.216.202.062.9836.8558.96-
Gross Margin50.9977.6480.3285.0199.0999.4987.7654.1573.11
Operating Margin-61.20-22.63-23.3923.7287.7892.93-55.27-169.03-45.88
Net Margin-61.40-39.59-24.1824.3654.5054.243.15-164.89-37.64
Shares Outstanding247.93251.33239.97237.73243.22242.52241.52226.7810.74
Market Capitalization21,621.8021,621.8027,318.3725,088.4436,456.1461,695.4019,369.717,564.557,794.53

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue1,483.25122.78138.171,056.151,775.03295.60192.391,269.36
Cost of Goods Sold Incl. D&A428.45330.62225.45387.94173.3186.6088.20259.74
Gross Profit1,054.80-207.83-87.28668.211,601.72209.01104.191,009.62
Selling, General and Administrative Excl. Other756.47652.80686.16841.87833.58732.78680.10793.51
Research and Development623.81514.38651.65588.25660.04577.04553.17652.60
Other Operating Expense107.110.000.0097.3024.6695.890.000.00
Operating Income191.22-860.64-773.44-270.96743.48-619.66-575.91216.11
Interest Expense4.034.074.687.570.473.856.740.00
Unusual Expense17.83223.01-22.23327.06710.99-136.58-127.77-581.88
Net Income Before Taxes255.42-998.42-664.64-264.6828.87-456.44-468.77321.29
Income Taxes43.14-44.07-42.3590.3262.40-18.25-31.1544.48
Consolidated Net Income212.27-954.35-622.28-355.00-33.54-438.19-437.61276.81
Net Income From Continuing Operations212.27-954.35-622.28-355.00-33.54-438.19-437.61276.81
Net Income212.27-954.35-622.28-355.00-33.54-438.19-437.61276.81
EPS (Recurring)0.89-3.18-2.52-0.511.93-2.22-2.19-0.54
EPS (Basic, Before Extraordinaries)0.86-3.80-2.46-1.45-0.14-1.82-1.821.15
EPS (Diluted)0.84-3.80-2.46-1.45-0.14-1.82-1.821.15
EBITDA573.53-551.24-631.53-79.15888.62-561.85-530.86392.54
Non-Operating Income (Expense)86.0689.3091.25340.92-3.1630.49-13.89-476.70
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense16.1117.0118.6720.0723.2325.9216.5717.86
Price To Sales Ratio8.877.566.887.036.718.197.379.18
Gross Margin71.11-169.27-63.1763.2790.2470.7154.1679.54
Operating Margin12.89-700.95-559.78-25.6641.89-209.62-299.3417.03
Net Margin14.31-777.27-450.38-33.61-1.89-148.24-227.4621.81
Shares Outstanding247.93251.20252.88251.33240.46240.40240.39239.97
Market Capitalization21,621.8023,530.8622,337.7722,891.3223,708.1525,594.6421,851.7627,318.37

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments17,429.0716,889.0112,884.3114,808.201,924.941,480.75582.74470.40206.66
Short Term Receivables1,156.721,578.002,584.557,626.5714,080.92203.5622.6832.5110.92
Inventories130.01293.36395.13469.16571.4478.4513.556.795.63
Other Current Assets247.57710.665,706.84492.32507.76242.513.210.842.25
Total Current Assets18,963.3719,471.0221,570.8323,396.2517,085.072,005.27622.19510.54225.47
Net Property, Plant & Equipment1,516.331,225.411,073.28876.32591.80398.82166.20132.57121.91
Total Investments and Advances2,917.921,298.521,299.1885.590.000.000.000.020.02
Long-Term Note Receivable2.3510.15-------
Intangible Assets2,318.251,212.571,288.68234.47230.17200.04100.39100.65100.31
Deferred Tax Assets15.8684.6089.81245.040.00197.28---
Other Assets90.4327.2392.136.9495.7535.546.582.682.25
Total Assets25,824.5123,329.5025,413.9124,844.6218,002.792,836.95895.36746.46449.96
Short Term Debt Incl. Current Port. of LT Debt61.3140.9031.0438.42147.7211.195.962.442.20
Accounts Payable628.21441.85391.05217.83181.95125.1523.0147.6963.09
Income Tax Payable77.044.66580.49635.971,784.150.010.170.340.00
Other Current Liabilities1,749.462,125.361,284.602,256.811,845.45605.13125.9393.70125.09
Total Current Liabilities2,516.022,612.772,287.183,149.033,959.28741.49155.06144.18190.38
Long Term Debt252.74222.32210.99188.05195.14282.7077.3461.9860.46
Provision for Risks Charges41.6921.649.729.18210.276.730.000.000.00
Deferred Tax Liabilities99.0143.9143.856.6275.850.34---
Other Liabilities337.18328.67497.5387.4136.73127.17109.00235.09257.00
Total Liabilities3,246.653,229.313,049.283,440.284,477.271,158.43341.41441.24507.84
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity22,577.8620,100.1922,364.6321,404.3413,525.521,678.52553.94304.25-59.19
Total Shareholders Equity22,577.8620,100.1922,364.6321,404.3413,525.521,678.52553.94304.25-59.19
Accumulated Minority Interest0.000.000.000.000.000.000.000.971.31
Total Equity22,577.8620,100.1922,364.6321,404.3413,525.521,678.52553.94305.22-57.89
Total Liabilities & Stockholders Equity25,824.5123,329.5025,413.9124,844.6218,002.792,836.95895.36746.46449.96
Book Value Per Share89.8483.7694.0888.0155.776.952.4428.33-
Tangible Book Value Per Share80.6178.7188.6687.0454.826.122.0018.96-
Full-Time Employees7,8076,7726,1334,5303,0821,9411,3101,032-
Price to Book Ratio1.071.281.192.034.5611.5717.2817.80-
Return on Assets-5.22-2.954.0046.28116.750.93-24.41-9.47-
Return on Equity-6.01-3.394.6056.77160.031.55-46.70-46.23-
Return on Invested Capital-5.62-3.544.4645.9288.670.88-31.75-15.47-7,640.60
Quick Ratio7.497.349.267.284.172.603.933.491.15
Current Ratio7.547.459.437.434.322.704.013.541.18

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-1,708.91-1,282.18-719.651,005.769,915.3112,165.5417.33-200.54-56.94
Depreciation1,024.85432.02322.34198.28129.5988.8844.1737.9425.94
Other Funds (Non Cash)576.92674.44-687.41-595.59-469.791,480.31212.8533.7710.69
Funds from Operations-31.87-92.32-1,095.64608.459,575.1113,734.7490.77-128.83-20.31
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-244.83606.951,320.315,198.654,694.39-12,683.13-106.13-93.39-48.32
Cash from Operating Activities-276.70514.63224.675,807.1014,269.501,051.61-15.36-222.21-68.64
Capital Expenditures-287.08-845.30-489.25-762.73-381.82-182.03-97.41-79.56-80.05
Net Assets From Acquisitions262.54210.250.00-364.230.00-24.59-69.13-6.780.00
Sale of Fixed Assets and Businesses8.265.081.300.000.634.021.410.020.83
Purchase or Sale of Investments834.70-2,155.92-1,763.26-6,391.66344.09-466.530.000.000.00
Purchase of Investments-10,943.01-12,891.18-13,380.84-7,706.62-50.24-466.530.000.000.00
Sale Or Maturity of Investments11,777.7110,735.2611,617.581,314.96394.330.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities818.43-2,785.89-2,251.21-7,518.62-37.10-669.12-165.12-86.31-79.22
Cash Dividends Paid0.000.000.000.00-508.990.000.000.000.00
Change in Capital Stock-469.170.000.00-798.40-920.55190.18858.41420.11426.74
Repurchase of Common Pref Stock-469.170.000.00-798.40-1,036.680.000.000.00-
Sale of Common Pref Stock0.000.000.000.00116.13190.18858.41420.11426.74
Proceedsfrom Stock Options0.000.000.000.00116.13190.18858.41420.11426.74
Issuance or Reduction of Debt, Net--12.75-2.490.22-18.92-62.17176.088.894.07
Change in Long Term Debt-------8.894.07
Issuance of Long Term Debt-------12.316.61
Reduction of Long Term Debt--------3.43-2.53
Net Financing Active Other Cash Flow-2.27-2.260.000.000.000.000.000.000.00
Other Financing Activities Uses-2.27-2.260.000.000.000.000.000.000.00
Cash from Financing Activities-382.35-59.70-49.65-841.76-1,491.65111.341,019.96429.00430.82
Exchange Rate Effect-4.05-30.4716.01-15.6862.6476.47-51.690.02-0.54
Net Change in Cash155.32-2,361.44-2,060.19-2,568.9512,803.39570.31787.79120.49282.42
Free Cash Flow-517.58317.02-264.585,536.7213,923.52900.91-102.95-265.41-104.74
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow-72.58-4.632.8074.31---
Deferred Taxes & Investment Tax Credit-83.40-10.930.000.000.00-183.570.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments15,832.6116,894.2016,864.2917,429.0716,893.5616,032.09
Short Term Receivables904.14280.34705.381,156.72921.791,698.21
Inventories73.72115.02119.60130.01265.20270.81
Other Current Assets992.62199.85206.47247.57520.52697.27
Total Current Assets17,803.0917,489.4017,895.7418,963.3718,601.0718,698.37
Net Property, Plant & Equipment1,317.701,392.881,518.831,516.331,457.821,458.04
Total Investments and Advances1,961.952,293.572,626.902,917.922,909.302,940.26
Intangible Assets1,791.922,052.112,209.112,318.252,053.312,172.91
Deferred Tax Assets22.7217.9516.9415.8620.8091.33
Other Assets17.0411.7814.0690.4328.9131.46
Total Assets22,914.4123,257.6924,281.5825,824.5125,075.7925,399.30
Short Term Debt Incl. Current Port. of LT Debt270.5665.4065.3361.3162.7461.51
Accounts Payable594.16739.37540.15628.21469.76591.86
Income Tax Payable14.9924.2443.9077.047.404.34
Other Current Liabilities1,202.071,399.511,384.251,749.462,071.531,514.85
Total Current Liabilities2,081.792,228.522,033.632,516.022,611.442,172.56
Long Term Debt305.77296.00283.56252.74225.60254.96
Provision for Risks Charges73.3867.0027.4241.6928.4326.88
Deferred Tax Liabilities93.8238.0760.9599.0128.4333.45
Other Liabilities241.82325.95332.41337.18471.061,189.23
Total Liabilities2,796.582,955.542,737.973,246.653,364.973,677.09
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity20,117.8320,302.1521,543.6122,577.8621,710.8321,722.21
Total Shareholders Equity20,117.8320,302.1521,543.6122,577.8621,710.8321,722.21
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity20,117.8320,302.1521,543.6122,577.8621,710.8321,722.21
Total Liabilities & Stockholders Equity22,914.4123,257.6924,281.5825,824.5125,075.7925,399.30
Book Value Per Share81.1480.8285.1989.8490.2990.36
Tangible Book Value Per Share73.9272.6576.4680.6181.7581.32
Full-Time Employees---7,807--
Price to Book Ratio1.071.090.991.051.091.25
Return on Assets-7.17-8.08-6.14-5.14-2.53-1.55
Return on Equity-8.22-9.35-6.90-5.93-2.94-1.81
Return on Invested Capital1.04-4.63-2.85-1.55-0.15-1.99
Quick Ratio8.527.808.747.497.028.48
Current Ratio8.557.858.807.547.128.61

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income223.34-959.37-622.28-350.59-64.79-434.11
Depreciation383.85311.06141.91188.03143.7456.86
Other Funds (Non Cash)12.31-78.43-44.69687.7340.14-94.10
Funds from Operations615.44-681.82-569.99604.50123.49-437.35
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-763.69694.3877.45-252.97730.58570.02
Cash from Operating Activities-148.2512.56-492.54351.53854.07132.67
Capital Expenditures-55.52-64.72-92.31-74.53-69.71567.96
Net Assets From Acquisitions-36.980.000.00299.52-3.17-2.66
Sale of Fixed Assets and Businesses1.713.971.870.703.310.56
Purchase or Sale of Investments1,013.31-58.073,191.45-3,311.98-925.2728.22
Purchase of Investments-1,726.31-2,402.84-1,813.62-5,000.24-3,401.80-1,899.36
Sale Or Maturity of Investments2,739.622,344.785,005.071,688.252,476.531,927.58
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities922.53-118.823,101.01-3,086.29-994.84-27.66
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock-318.10-151.070.000.000.000.00
Repurchase of Common Pref Stock-318.10-151.070.000.000.000.00
Sale of Common Pref Stock0.000.000.000.000.000.00
Proceedsfrom Stock Options0.000.000.000.000.000.00
Issuance or Reduction of Debt, Net61.0537.3944.81-2.21-1.68-4.17
Net Financing Active Other Cash Flow0.000.000.00-2.270.000.00
Other Financing Activities Uses0.000.000.00-2.270.000.00
Cash from Financing Activities-269.92-126.8830.89-16.44-14.05-14.92
Exchange Rate Effect2.37-3.86-3.981.41-24.519.45
Net Change in Cash506.73-237.002,635.38-2,749.79-179.3399.54
Free Cash Flow-186.59-51.24-558.99279.25810.54700.63
Price to Free Cash Flow-48.7418.2573.34--

Revenue breakdown

COVID-9 Vaccine Revenues2024: 2.63B 2025: 2.25B
Other Sales2024: 345.15M 2025: 295.06M
Revenues from out-licensing2025: 691.41M
Germany2024: 764.84M 2025: 856.20M
Ireland2024: 192.37M 2025: 343.79M
Rest of the World2024: 20.12M 2025: 12.52M
United States2024: 2.00B 2025: 2.02B

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-300.91%2.2M246.9M1.26M
2026-10-150.91%2.3M250.1M1.20M
2026-09-301.00%2.5M250.1M1.15M
2026-09-150.93%2.3M250.1M1.16M
2026-08-310.92%2.3M250.1M1.20M
2026-08-141.00%2.5M250.1M954.39K
2026-07-310.99%2.5M250.3M926.63K
2026-07-150.90%2.3M251.9M955.63K
2026-06-300.92%2.3M251.9M950.28K
2026-06-151.09%2.7M251.9M983.85K
2026-05-290.90%2.3M251.9M1.20M
2026-05-150.97%2.5M251.9M1.13M
2026-04-300.88%2.2M251.9M1.10M
2026-04-151.29%3.2M250.4M1.14M
2026-03-311.40%3.5M250.4M1.17M
2026-03-131.41%3.5M250.4M1.22M
2026-02-271.86%4.5M239.6M1.06M
2026-02-131.97%4.7M239.6M1.14M
2026-01-302.09%5.0M238.8M1.17M
2026-01-152.03%4.8M238.8M1.07M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call65.0020.3024.100.001.9220.000.000.967-0.0660.010
call70.0015.3019.100.001.5750.000.000.886-0.1910.026
call75.0010.4014.2022.991.2653.000.000.857-0.1730.031
call80.005.509.600.000.9941.000.000.798-0.1570.039
call82.503.407.400.000.8750.000.000.737-0.1570.045
call85.002.704.205.000.52043.000.000.648-0.1560.051
call87.501.802.601.950.4796042.000.513-0.1580.055
call90.000.351.601.500.4821490.000.374-0.1490.052
call92.500.451.000.850.5031,8330.000.287-0.1550.047
call95.000.100.700.490.5551201.000.188-0.1200.037
call97.500.000.500.430.58756.000.000.129-0.0950.029
call1000.002.300.300.7811,5790.000.144-0.1350.031
call1050.000.850.130.9601,7040.000.123-0.1490.028
call1100.000.900.151.0701,2980.000.109-0.1470.027
call1150.001.450.051.2713610.000.099-0.1680.024
call1200.001.150.101.4071360.000.091-0.1750.023
call1250.001.800.261.53668.000.000.085-0.1820.021
call1300.002.150.251.6591300.000.080-0.1880.020
call1350.001.801.051.7731190.000.076-0.1930.020
call1400.000.850.101.6284.000.000.051-0.1240.015
put65.000.000.200.101.02423.000.00-0.033-0.0540.010
put70.000.001.350.171.29529.000.00-0.120-0.1950.027
put75.000.001.200.100.7833870.00-0.106-0.1030.026
put80.000.051.050.450.6893310.00-0.197-0.1470.038
put82.500.351.050.750.5264000.00-0.264-0.1480.045
put85.001.251.851.490.5414710.00-0.350-0.1460.051
put87.501.952.952.370.52060.001.00-0.496-0.1480.055
put90.003.404.504.300.5501971.00-0.626-0.1390.052
put92.504.408.008.000.8943820.00-0.715-0.1440.047
put95.006.7010.209.600.9793470.00-0.809-0.1110.037
put97.508.7012.5011.201.05216.000.00-0.872-0.0850.029
put10011.1015.0011.601.16275.000.00-0.873-0.1040.029
put10516.0019.9017.511.34240.000.00-0.893-0.1150.025
put11021.0024.9019.961.54611.000.00-0.905-0.1230.023
put11526.0029.900.001.6900.000.00-0.901-0.1550.024
put12031.0034.800.001.8560.000.00-0.921-0.1360.020
put12536.0039.800.001.9700.000.00-0.915-0.1680.021
put13040.9044.800.002.1100.000.00-0.920-0.1740.020
put13545.9049.800.002.2410.000.00-0.924-0.1780.020
put14050.9054.800.002.4450.000.00-0.945-0.1300.015

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-106-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-11-10SEC
2026-11-036-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-30SEC
2026-11-036-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-11-03SEC
2026-10-266-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-26SEC
2026-10-266-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-26SEC
2026-10-226-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-22SEC
2026-10-196-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-19SEC
2026-10-136-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-13SEC
2026-10-094Statement of changes in beneficial ownership of securities2026-10-08SEC
2026-10-074Statement of changes in beneficial ownership of securities2026-10-07SEC
2026-10-064Statement of changes in beneficial ownership of securities2026-10-05SEC
2026-10-024Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-09-304Statement of changes in beneficial ownership of securities2026-09-29SEC
2026-09-284Statement of changes in beneficial ownership of securities2026-09-25SEC
2026-09-244Statement of changes in beneficial ownership of securities2026-09-23SEC
2026-09-224Statement of changes in beneficial ownership of securities2026-09-21SEC
2026-09-184Statement of changes in beneficial ownership of securities2026-09-17SEC
2026-09-186-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-18SEC
2026-09-164Statement of changes in beneficial ownership of securities2026-09-15SEC
2026-09-144Statement of changes in beneficial ownership of securities2026-09-11SEC
2026-09-146-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-14SEC
2026-09-114Statement of changes in beneficial ownership of securities2026-09-10SEC
2026-09-094Statement of changes in beneficial ownership of securities2026-09-08SEC
2026-09-084Statement of changes in beneficial ownership of securities2026-09-03SEC
2026-09-03144Filing for proposed sale of securities under Rule 144.SEC
2026-08-286-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-28SEC
2026-08-276-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-27SEC
2026-08-206-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-20SEC
2026-08-046-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-30SEC
2026-08-046-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-04SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100020.58M7
2026-090063.65M19
2026-080000
2026-070000
2026-060000
2026-050000
2026-04005.53M1
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
FMR LLC3.90%
PRIMECAP MANAGEMENT CO/CA/1.49%
DODGE & COX1.45%
T. Rowe Price Investment Management, Inc.0.82%
BlackRock, Inc.0.73%
BNP PARIBAS FINANCIAL MARKETS0.52%
Temasek Holdings0.49%
Logos Global Management LP0.40%
FIRST TRUST ADVISORS LP0.31%
Assenagon Asset Management S.A.0.30%

Funds

Fund% owned
Fidelity Contrafund1.30%
Dodge & Cox International Stock Fund1.00%
VANGUARD CAPITAL OPPORTUNITY FUND0.87%
T. Rowe Price Mid-Cap Growth Fund, Inc.0.40%
PRIMECAP Odyssey Aggressive Growth Fund0.35%
First Trust NYSE Arca Biotechnology Index Fund0.31%
Fidelity Contrafund K60.28%
Fidelity Emerging Markets Fund0.26%
iShares Biotechnology ETF0.26%
Dodge & Cox Global Stock Fund0.21%

OakChart. BNTX. Cached 15 minutes.